Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis

Objective To investigate liver enzyme abnormalities and hepatic adverse events (AEs) during long‐term tocilizumab treatment for rheumatoid arthritis in clinical trials. Methods Data were pooled from patients who received intravenous tocilizumab (4, 8, or 10 mg/kg with or without disease‐modifying an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2017-09, Vol.69 (9), p.1751-1761
Hauptverfasser:	Genovese, Mark C., Kremer, Joel M., van Vollenhoven, Ronald F., Alten, Rieke, Scali, Juan Jose, Kelman, Ariella, Dimonaco, Sophie, Brockwell, Laura
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities Adult Aged Alanine Alanine transaminase Alanine Transaminase - blood Antibodies, Monoclonal, Humanized - adverse effects Antirheumatic Agents - adverse effects Arthritis Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - drug therapy Aspartate aminotransferase Aspartate Aminotransferases - blood Chemical and Drug Induced Liver Injury - epidemiology Chemical and Drug Induced Liver Injury - etiology Clinical trials Confidence intervals Dose-Response Relationship, Drug Drugs Exposure Female Humans Immunosuppressive agents Intravenous administration Liver Liver - drug effects Liver - enzymology Male Medical research Middle Aged Monoclonal antibodies Patients Pharmacology Randomized Controlled Trials as Topic Rheumatoid arthritis Transaminase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!